FDA removes black-box warnings from 3 menopause patches

FDA officials said Friday that three more estrogen patches for menopause will no longer carry black-box warnings for cardiovascular disease, breast cancer and dementia, according to a Guardian Health report.

The change expands a February label revision from six menopause treatments to nine products. It also brings renewed scrutiny to the FDA’s process because the agency did not convene an advisory committee, the report said.

A black-box warning is the FDA’s most prominent drug-label safety alert. In the Friday press briefing, FDA officials gave few details on the evidence behind the latest change and told journalists the supporting evidence could be provided later, according to the report.

“I have been concerned by the lack of transparency behind these decisions,” said Reshma Ramachandran, an assistant professor and health services researcher at Yale School of Medicine. “The blanket removal of black-box warnings regarding risks of breast cancer and cardiovascular disease without clear justification can be misleading for patients and underplays real potential harms.”

Ramachandran said risks may be higher for some patients, including people with histories of hormone-sensitive cancers.

FDA officials instead emphasized access problems. Dorothy Fink, deputy director of the National Institute of Child Health and Human Development, said, “We are working with manufacturers to strengthen supply and improve access.” She said manufacturing of estrogen patches had doubled over the past year.

Sarah Ibrahim, deputy center director for regulatory programs at the FDA’s Center for Drug Evaluation and Research, said demand for estradiol patches rose after the February label change and that patients in many areas had difficulty filling prescriptions at their usual pharmacies. “And I want you to know that we hear you,” she said.

Ibrahim said the prior warnings “painted a broad and, in some cases, overstated pictures of risk.” She said “updated evidence” indicates that many healthy women younger than 60 and within 10 years of menopause onset have a different risk-benefit profile than the older labels suggested.

The Guardian report said estradiol patches are generally viewed as lower risk than synthetic oral medications because the hormone enters the bloodstream without first passing through the liver. It also cited research indicating that risks are higher at higher patch doses.

The process remains disputed. The FDA also bypassed advisory committees last November when it announced plans to remove warnings; a spokesperson at the time said committees were “bureaucratic, long, often conflicted, and very expensive,” according to the report.

The agency is working with manufacturers to increase production and is also changing labels for remaining menopause hormone treatment products, Ibrahim said. The FDA is also exploring whether vaginal estrogen products could be sold over the counter, according to an agency press release cited in the report.

Source: Guardian Health news report, Oct. 30, 2026.

Atlas360 reports health research and does not provide medical advice.